Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 351

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

Blood‐based biomarkers for Alzheimer's disease

Open access
Leuzy, Antoine, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Janelidze, Shorena, Dage, Jeffrey L, Hansson, Oskar·2022·EMBO Molecular Medicine

Abstract

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202114408

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 157 references

Cited by

See all 351

Metadata

Authors
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O.
Venue
EMBO Molecular Medicine
Published
2021-12-03
Volume
14
Issue
1
Pages
e14408-e14408
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3214939633
Cited by
351
References
157
FWCI
29.67
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood‐based biomarkers for Alzheimer's disease. https://app.cochat.ai/papers/10.15252/emmm.202114408
The paper
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood‐based biomarkers for Alzheimer's disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202114408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.